#United States #Frederick #Biopharmaceutical #BioFactura #Capitol Biologics

BioFactura's Capitol Biologics: Driving Innovation in Biologics Development

BioFactura, Inc., a notable player in the biopharmaceutical sector located in Frederick, Maryland, has recently announced the rollout of its new division, Capitol Biologics. This strategic initiative is designed to provide comprehensive support in the development and manufacturing of biologics, catering primarily to early-stage biotechnology companies and government agencies.

In an industry characterized by rapid advancements and escalating complexities, Capitol Biologics aims to streamline the journey from concept to market. With a focus on vital areas such as process development, early-phase clinical manufacturing, and analytical support, this new Contract Development and Manufacturing Organization (CDMO) is set to redefine service standards within the sector.

Expertise Backed by Two Decades of Experience

Having spent nearly 20 years honing its expertise in biologics development, BioFactura leverages its profound knowledge to offer a full range of phase-appropriate manufacturing solutions. These include the fabrication of monoclonal antibodies, recombinant proteins, and other intricate biologics which are crucial in today's medical landscape. The division prides itself on utilizing advanced technologies in cell line development, upstream and downstream optimization, and good manufacturing practices (GMP) that adhere to rigorous global regulatory standards including those from the FDA, EMA, and ICH.

A Strategic Location

Located strategically within the greater Washington, D.C. area and the I-270 Biotech Corridor, Capitol Biologics enjoys close proximity to major pharmaceutical hubs, critical government facilities, and esteemed research institutions. This geographical advantage facilitates streamlined logistics, ensuring a robust support system for both private sector innovations and public health initiatives, particularly those aimed at bolstering national preparedness.

Leadership with Vision

Darryl Sampey, President and CEO of BioFactura, expressed his enthusiasm regarding this evolution, stating how the transformation of BioFactura's development capabilities into a dedicated service organization presents invaluable benefits to emerging ventures. The experience and insights garnered over the decades allow Capitol Biologics to deliver solutions that are not only cost-effective but also essential for the survival and success of client projects.

Echoing a similar sentiment, Dr. Jeffrey Hausfeld, Chairman and Chief Medical Officer, elaborated on the division's mission to merge proven technical proficiency with a personalized service model. This dual focus is geared towards propelling therapeutic innovations into clinical realities at unprecedented speeds while adhering strictly to high-quality standards.

Innovation and Problem Solving at the Core

The ethos of Capitol Biologics is deeply rooted in innovation and problem-solving. Emphasizing their agility, the team at Capitol Biologics aims to effectively respond to client needs without the extraneous hurdles that typically plague early-stage biotech projects. This ensures that clients are not only 'Fit For Purpose' but are also assured that their underlying challenges are addressed through a seamless service experience.

Commitment to Quality and Client Collaboration

Capitol Biologics sets ambitious standards in terms of quality, innovation, and collaborative engagement with clients. By providing integrated capabilities encompassing cell line development, process optimization, GMP manufacturing, and meticulous analytical services, Capitol Biologics acts as a guiding hand for biotech firms transitioning from concept inception to clinical trials.

As the need for innovative biologic solutions accelerates, both locally and globally, Capitol Biologics stands ready to make a considerable impact. Its commitment to excellence and client-focused approaches positions it as a pivotal player in the advancement of therapeutic solutions that cater to pressing healthcare needs.

In summary, with the launch of Capitol Biologics, BioFactura is poising itself at the forefront of the biopharmaceutical landscape—where dedication to quality, expedited development, and client success converge seamlessly. As this new chapter unfolds for BioFactura and its clients, the future of biologics development looks promising and potent.